VNDA — what changed in the latest 10-Q
A section-by-section comparison of VNDA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-05-07
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +119 | −79 | ~84 | 92 |
| Market risk (Item 3) | Text added/removed | +119 | −79 | ~84 | 91 |
| Controls & procedures | Text added/removed | +119 | −79 | ~84 | 91 |
| Legal proceedings | Text added/removed | +119 | −79 | ~84 | 91 |
| Risk factors | Some risk factors updated | +119 | −79 | ~84 | 91 |
| Other information | Text added/removed | +119 | −79 | ~84 | 91 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
•our ability to generate sales of NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
Tax benefit (provision) on other comprehensive income (loss)— 22 — (69)
Issuance of common stock from the exercise of stock options and settlement of equity awards319,625 — — — — —
Issuance of common stock from the exercise of stock options and settlement of equity awards146,648 — — — — —
•HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
Text removed vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•BYSANTITM (milsaperidone) for major depressive disorder (MDD);
•HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
•PONVORY® (ponesimod) for the treatment of ulcerative colitis and psoriasis;
•Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-06
•our ability to generate sales of NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
Tax benefit (provision) on other comprehensive income (loss)— 22 — (69)
Issuance of common stock from the exercise of stock options and settlement of equity awards319,625 — — — — —
Issuance of common stock from the exercise of stock options and settlement of equity awards146,648 — — — — —
•HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
Text removed vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•BYSANTITM (milsaperidone) for major depressive disorder (MDD);
•HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
•PONVORY® (ponesimod) for the treatment of ulcerative colitis and psoriasis;
•Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-06
•our ability to generate sales of NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
Tax benefit (provision) on other comprehensive income (loss)— 22 — (69)
Issuance of common stock from the exercise of stock options and settlement of equity awards319,625 — — — — —
Issuance of common stock from the exercise of stock options and settlement of equity awards146,648 — — — — —
•HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
Text removed vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•BYSANTITM (milsaperidone) for major depressive disorder (MDD);
•HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
•PONVORY® (ponesimod) for the treatment of ulcerative colitis and psoriasis;
•Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-06
•our ability to generate sales of NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
Tax benefit (provision) on other comprehensive income (loss)— 22 — (69)
Issuance of common stock from the exercise of stock options and settlement of equity awards319,625 — — — — —
Issuance of common stock from the exercise of stock options and settlement of equity awards146,648 — — — — —
•HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
Text removed vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•BYSANTITM (milsaperidone) for major depressive disorder (MDD);
•HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
•PONVORY® (ponesimod) for the treatment of ulcerative colitis and psoriasis;
•Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-06
•our ability to generate sales of NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
Tax benefit (provision) on other comprehensive income (loss)— 22 — (69)
Issuance of common stock from the exercise of stock options and settlement of equity awards319,625 — — — — —
Issuance of common stock from the exercise of stock options and settlement of equity awards146,648 — — — — —
•HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
Text removed vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•BYSANTITM (milsaperidone) for major depressive disorder (MDD);
•HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
•PONVORY® (ponesimod) for the treatment of ulcerative colitis and psoriasis;
•Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-06
•our ability to generate sales of NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion in the U.S., including through direct-to-consumer sales with the nereus.us website;
Tax benefit (provision) on other comprehensive income (loss)— 22 — (69)
Issuance of common stock from the exercise of stock options and settlement of equity awards319,625 — — — — —
Issuance of common stock from the exercise of stock options and settlement of equity awards146,648 — — — — —
•HETLIOZ® for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
Text removed vs the prior filing · source: 10-Q · 2026-05-07
•our ability to commercialize NEREUSTM (tradipitant) capsules for the prevention of vomiting induced by motion;
•BYSANTITM (milsaperidone) for major depressive disorder (MDD);
•HETLIOZ® (tasimelteon) for the treatment of jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder (DSPD) and pediatric Non-24;
•PONVORY® (ponesimod) for the treatment of ulcerative colitis and psoriasis;
•Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis (GPP);
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice